Downregulation of NOTCH1 signaling in mesenchymal stem cells from multiple myeloma patients leads to an elevated expression of hsa-miR-223-3p and a decrease in the VEGFA level [32]. The gene discussed is VEGFA; the disease is plasma cell myeloma.